Clinical TrialsThe PrMS cohort is fully enrolled, which positions the company well to finalize a dose with high receptor occupancy.
Market PotentialThe market opportunity for new treatments in idiopathic pulmonary fibrosis is large, as evidenced by significant sales of existing treatments.
Safety ProfileContineum is developing PIPE-791, which has shown a competitive advantage by maintaining a clean safety profile in Phase I trials.